Encouraging results for RADIODETECT
14.10.25
Neolys Diagnostics and Professor Vogin have developed a radiation sensitivity test called “RADIODTECT” which uses a blood sample to detect a patient's potential risk of developing toxicities. These radiosensitivity tests are designed to help oncologists tailor treatments to patients' sensitivity and offer personalized medicine.
A clinical study, APRILUX, was launched in 2023 with the aim of observing the severity of side effects described by patients and attempting to establish correlations between these observations and the blood test's prognoses, and ultimately to evaluate its predictive capabilities. 200 patients were included between October 2023 and May 2024.
The preliminary results of this study are encouraging and show that it is becoming possible to further personalize the patient's treatment pathway by adapting it to the level of toxicity risk without sacrificing therapeutic efficacy (alternatives to RT, preventive care for at-risk patients, more precise techniques (proton therapy, brachytherapy, etc.), metabolic imaging, etc.).
A one-year follow-up will allow for further evaluation of the long-term predictive capabilities of this test.